Naproxennatrium Etos (Naproxen Sodium)

Naproxen sodium blocks the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are required for prostaglandin synthesis. By lowering prostaglandin levels, it reduces inflammation, diminishes pain signaling, and helps lower fever.

The appropriate dose of Naproxennatrium Etos is determined by the prescribing clinician based on the patient’s condition, age, renal and hepatic function, and other individual factors. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for naproxen sodium in pregnancy are limited, and the drug is generally avoided in the third trimester because of potential fetal cardiovascular effects. Use during breastfeeding is possible but should be discussed with a healthcare professional, as small amounts may be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both naproxen and ibuprofen are NSAIDs that inhibit COX enzymes, but naproxen has a longer half‑life, allowing less frequent dosing. Naproxen may carry a slightly higher risk of cardiovascular events with long‑term use, while ibuprofen is often associated with a higher incidence of gastrointestinal irritation in short‑term therapy.

Store the product at ambient temperature, preferably below 25 °C, in its original packaging to protect it from moisture and light. Keep the container tightly closed and out of reach of children. Do not store in areas with high humidity or direct sunlight.

Naproxennatrium Etos is taken orally, usually with a full glass of water. It can be taken with or without food, although taking it with food may reduce gastrointestinal discomfort. The tablet should be swallowed whole and not crushed or chewed unless specifically instructed by a healthcare professional.

Serious risks include gastrointestinal bleeding or ulceration, cardiovascular events such as heart attack or stroke, acute kidney injury, severe skin reactions (e.g., Stevens‑Johnson syndrome), and liver injury. Patients should seek immediate medical attention if they notice signs of bleeding, chest pain, sudden swelling, or severe rash.

Individuals with a known hypersensitivity to naproxen or other NSAIDs, active gastrointestinal ulceration, severe heart failure, uncontrolled hypertension, advanced renal or hepatic disease, and those in the third trimester of pregnancy should avoid using Naproxennatrium Etos unless a physician determines that benefits outweigh the risks.